Abstract # 2377 A Phase III, Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region

Presenter: Chambers, Mark

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

About the Presenter:
Dr. Mark S. Chambers is an Associate Professor in the Department of Head and Neck Surgery and Department of Radiation Oncology at The University of Texas M. D. Anderson Cancer Center. He is the Director of Clinical Research in the Department of Head and Neck Surgery.

Authors:
M. S. Chambers*1, K. Hodge*2, J. Holland*3, C. Jones*4, R. Vitti*5, A. S. Garden*1, R. I. Haddad*6. , 1The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2Commonwealth Ear, Nose & Throat, Louisville, KY, 3Oregon Health and Science University, Portland, OR, 4Radiological Associates of Sacramento Medical Group, Inc., Sacramento, CA, 5Daiichi Pharmaceutical Co. (currently an employee of Novartis Pharmaceuticals Co.), Montvale, NJ, 6Dana-Farber Cancer Institute, Boston, MA,

Author Disclosure:
M.S. Chambers, Daiichi Pharmaceutical Co., B. Research Grant; K. Hodge, Daiichi Pharmaceutical Co., B. Research Grant; J. Holland, Daiichi Pharmaceutical Co., B. Research Grant; C. Jones, Daiichi Pharmaceutical Co., B. Research Grant; R. Vitti, Formerly at Daiichi Pharmaceutical Co., A. Employment; A.S. Garden, Daiichi Pharmaceutical Co., B. Research Grant; R.I. Haddad, Daiichi Pharmaceutical Co., B. Research Grant.


E-mail a friend about this abstract:
Enter email address:   



Abstracts Main Page | Logout